Effects of Empagliflozin-Metformin, Sitagliptin-Metformin, and Metformin on Adipokines in Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 186 participants.

Also called NCT07531108

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 186 participants (enrolled count) (from the registry)
Sponsor
Hawler Medical University (from the registry)
Registry
  • NCT NCT07531108
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Iraq (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07531108. Non-randomized; no masking; primary purpose treatment. Start 2024-11-15 (actual); primary completion 2025-11-27 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of Empagliflozin-Metformin, Sitagliptin-Metformin, and Metformin on Adipokines in Type 2 Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Empagliflozin-Metformin
Intervention (Drug)
Sitagliptin-Metformin
Intervention (Drug)
Metformin
Lead sponsor
Hawler Medical University (class: other)

Record details

Record id
cardio:ct-nct07531108
Content hash
5479bc763b346b17d827447e9e1fb3f11bbcb122d38b9ab865a2f24a32001969